EU Food Supplement Maximum Levels: The Harmonisation Gap That's Tripping Up Multi-Market Brands

A French supplement brand formulated a vitamin D3 product at 50 µg per daily serving. They had checked the French guidance, understood the ANSES position, and built a clean product file. Six months after launch in France, they approached a German distributor. The rejection came back quickly: Germany’s BfR position caps vitamin D from supplements at 20 µg/day for general consumers without medical supervision. Same molecule, same dose, same European single market — commercially blocked in a neighbouring country.

That scenario plays out across product categories and nutrient combinations more often than most brands admit. The reason comes down to a 24-year-old regulatory promise that’s never been fulfilled.

How Article 5 of Directive 2002/46/EC Created a Compliance Puzzle That Still Isn’t Solved

The EU Food Supplements Directive (2002/46/EC), adopted in June 2002, harmonised two things effectively: the list of permitted vitamin and mineral forms that may be used in supplements (Annexes I and II) and the basic labelling obligations. What it explicitly deferred — and what its Article 5 promised would follow — was the setting of maximum and minimum levels for nutrients in finished supplement products.

The Commission was tasked with establishing those limits, taking into account EFSA’s safe upper intake levels, EU-wide nutrient reference values, and intake data from population studies. The process began in earnest. EFSA published extensive opinions. Consultations were held. Draft approaches circulated. And then the political complexity of aligning 27 national food safety traditions proved more tractable than expected.

Article 5(4) of the Directive allows member states to maintain their existing national rules on maximum levels in the interim — and “interim” has now stretched to 2026. The practical result is a patchwork of national frameworks: some are formal regulations, some are recommendations from national risk assessment bodies, and some are grey zones where only the general food safety obligation under Regulation (EC) No 178/2002 applies.

For a brand formulating a single product and hoping to sell it across the EU, those 27 frameworks matter enormously. And for brands with additional ambitions in Canada or the United States, the picture gets more fragmented still.

What the Numbers Actually Look Like: Three Nutrients Across Four Markets

Abstract regulatory complexity is easier to understand with concrete examples. Three commonly problematic nutrients illustrate the range well.

Vitamin D

France: ANSES guidance points to 25 µg/day (1,000 IU) as the maximum for general-population supplement use. Products exist above this level in the French market, but 25 µg is the accepted prudent limit for compliant product files.

Germany: The BfR recommends a maximum daily dose of 20 µg (800 IU) from supplements for adults without medical supervision. This recommendation carries significant weight with German market surveillance authorities and distributors alike.

Netherlands: The NVWA and the Dutch Health Council reference EFSA data more directly, and products at 75 µg/day (3,000 IU) are routinely available without question.

Ireland: Tends to follow the EFSA tolerable upper intake level of 100 µg/day (4,000 IU) as the relevant benchmark, making it one of the more permissive EU markets for higher-dose vitamin D.

A brand formulating at 50 µg/day — a dose that is not unusual in modern sports nutrition or bone health products — has a product that’s broadly accepted in Ireland and the Netherlands, sits in contested territory in France, and faces serious obstacles in Germany. That’s not a theoretical risk tolerance question. That’s a reformulation decision with real cost implications, because reformulations in a GMP-certified facility involve stability studies, updated specifications, and revised labels across all packaging formats.

Vitamin B6

Germany’s BfR limits vitamin B6 from supplements to 3.5 mg/day for long-term general use — a recommendation grounded in concerns about peripheral neuropathy at high chronic intakes. France sets 5.4 mg/day as its ANSES-referenced maximum. EFSA’s established tolerable upper intake level for adults is 25 mg/day. Brands frequently cite the EFSA UL as if it were a product limit. It isn’t. It’s a health-risk threshold — the level below which no adverse effects were identified in the general adult population. Regulatory ceilings set by national authorities are almost always lower, often substantially so.

Folic Acid

Belgium has a formal royal decree limiting folic acid in supplements to 200 µg/day. Spain references the Scientific Committee on Food’s 2000 opinion but has no formal national ceiling. The Netherlands allows up to 1,000 µg/day in generally available supplements. For a product targeting maternal health across three EU markets, these differences drive not just formulation decisions but claim language, target-audience declarations, and risk messaging on labels.

When You Add Canada and the US, the Matrix Gets Harder to Manage

For European brands with export ambitions beyond the EU, each additional jurisdiction introduces a separate maximum-level framework.

Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) licences Natural Health Products (NHPs) against specific product monographs or through individual evidence reviews. Maximum doses for vitamins and minerals are often specified directly in the applicable monograph — and they frequently sit well below what any EU member state accepts.

For vitamin D, Health Canada monographs for general adult supplement use typically allow up to 1,000 IU (25 µg) per day. Going above that level requires making a disease risk reduction claim — a materially different regulatory pathway, with different evidence requirements and significantly longer approval timelines. A European product formulated at 50 µg/day for general wellbeing positioning will not qualify under the standard NHP monograph. The brand either reformulates down, or accepts the 12-to-18-month timeline of a claim-supported NHP licence application.

For vitamin B6, Health Canada monographs for general adult use commonly allow up to 50 mg/day — more permissive than Germany, broadly aligned with EFSA’s risk position. But the point is that the brand is now tracking a third distinct framework for a single nutrient.

The FDA’s approach under DSHEA is structurally different from both the EU and Canada. There are no FDA-set maximum levels for vitamins and minerals in dietary supplements. Safety is assessed against a “reasonable expectation of safety” standard, and FTC substantiation requirements apply to any implied claims. High-dose vitamin D products at 10,000 IU or higher exist legally in the US market, though brands selling them carry the evidentiary burden if the FDA or FTC challenges them.

Three jurisdictions, three frameworks for vitamin D: 20 µg (Germany), 25 µg (Health Canada monograph pathway), 100 µg (EFSA UL-referenced). Brands that don’t map this before finalising a formula discover it at the worst possible time.

Building a Multi-Jurisdiction Compliance File Before You Lock a Formula

The practical response to this landscape isn’t waiting for EU harmonisation — that may take another decade, and there’s no guarantee it will simplify anything when it arrives. It’s building jurisdiction-specific documentation discipline from the start.

Map dosages against all target markets before formula lock. A product formulated at the German BfR recommendation (20 µg vitamin D) is commercially conservative but maximally portable across EU markets. A product at 75 µg is optimised for the Netherlands or Ireland but effectively excludes Germany without a medical-use positioning. Neither choice is wrong — but it has to be a deliberate choice, made before stability studies begin.

Distinguish regulatory ceilings from EFSA tolerable upper intake levels in every internal document. This sounds basic. It isn’t, in practice. We’ve reviewed compliance files for established European brands where the justification for a maximum level was simply a copy-paste of the EFSA UL, with no reference to the relevant national authority’s position. That file does not survive a German BfR query or a French DGCCRF inspection.

Document your scientific justification for each market. If your formulation exceeds a national body’s recommendation, you need a file explaining why your product is safe at that level in that population — citing the relevant EFSA opinion, any peer-reviewed literature, and your own product’s safety assessment. The EU Cosmetics Regulation framework has normalised the Product Information File concept for personal care; supplement brands need an equivalent for their dosage rationale.

For Canadian NHP licensing, assess the monograph pathway early. European brands frequently assume that a product cleared for the EU market should move quickly through Health Canada. In practice, a high-dose vitamin D or B6 formulation may require a full new product licence application rather than a standard monograph submission — adding cost and time that wasn’t in the market entry budget.

Test your finished product against a comparative multi-jurisdiction limit report, not just a single-market COA. Our team produces certificates of analysis that map results against EU, Health Canada, and relevant national-authority limits side by side. Seeing a single COA number doesn’t tell you whether your product is compliant in Berlin, Brussels, and Toronto simultaneously. A comparative view does.

The 2002 Promise Isn’t Coming to Save You

Article 5 of the Food Supplements Directive is still on the books. The Commission still intends to harmonise maximum levels. EFSA’s scientific work on this is extensive and genuinely rigorous. But after 24 years of regulatory process, the pragmatic position for any brand is to treat harmonisation as a future event, not a current protection.

The brands that navigate this well are the ones that treat each market’s maximum-level framework as a compliance input to formulation — not a post-launch problem to manage. Get the matrix built before the formula is final, and the downstream compliance work becomes documentation rather than renegotiation.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry and multi-jurisdiction supplement compliance. Contact us

Related from our network

• ISO 17025-accredited supplement testing against US FDA and multi-market limits — Qalitex Laboratories provides finished-product testing with jurisdiction-comparative COA reporting for brands targeting the US market.
• Health Canada NHP licence applications for European supplement brands entering Canada — Androxa supports European brands through the NHP product licence pathway, including monograph assessment and dosage compliance review.